[Serious infections after treatment with infliximab].
Broholm
Berit
B
Amtssygehuset i Herlev, Medicinsk Afdeling Q. berit.broholm@dadlnet.dk
Gjørup
Ida E
IE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000209:etiology / Q000276:immunology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D013290:Streptococcal Infections / Q000209:etiology / Q000276:immunology*; D013297:Streptococcus pyogenes / Q000302:isolation & purification
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab